Protinhi Therapeutics is awarded €7.5 Million by the European Commission to develop the first-in-class broad-spectrum antiviral drug against dengue and other flaviviruses
1 mei 2023
The funding will be dedicated to developing our broad-spectrum pan-flavi antiviral drug PTL- 244 to clinical phase II stage for the most common flavivirus: dengue. Dengue is endemic in more than 100 countries (a.o. Singapore, Brazil, Thailand and India) and 400 million people get infected annually. Currently, there is no